Journal of General Internal Medicine

, Volume 15, Issue 11, pp 776–781 | Cite as

Adherence to guidelines for oral anticoagulation after venous thrombosis and pulmonary embolism

  • David A. Ganz
  • Robert J. Glynn
  • Helen Mogun
  • Eric L. Knight
  • Rhonda L. Bohn
  • Jerry Avorn
Original Articles

Abstract

OBJECTIVE: Guidelines for oral anticoagulation after deep venous thrombosis (DVT) or pulmonary embolism (PE) have recommended that patients be anticoagulated for at least 3 months after hospital discharge. We sought to determine whether this recommendation was being followed and what patient characteristics predict a shorter than recommended duration of therapy.

DESIGN: Retrospective cohort study using linked health care claims data.

SETTING: Routine clinical practice.

PATIENTS: Five hundred seventy-three members of New Jersey’s Medicaid or Pharmacy Assistance for the Aged and Disabled programs aged 65 years and older who were hospitalized for DVT or PE between January 1, 1991 and June 30, 1994.

RESULTS: Of the 573 patients, 129 (23%) filled prescriptions covering less than 90 days of oral anticoagulant therapy. In multivariate models, African-American race was associated with an increased risk of a shorter than recommended duration of therapy (odds ratio [OR], 1.87; 95% confidence interval [CI], 1.14 to 3.08), but age and gender were not. Patients who used anticoagulants in the year prior to admission were less likely to have a short duration of therapy (OR, 0.30; 95% CI, 0.12 to 0.78), than were patients with PE (OR, 0.58; 95% CI, 0.38 to 0.88).

CONCLUSIONS: Nearly a quarter of those anticoagulated following DVT or PE received therapy for less than the recommended length of time after hospital discharge, with African Americans more likely to have a shorter than recommended course of treatment. Further research is needed to evaluate the causes of shorter than recommended duration of therapy and racial disparities in anticoagulant use.

Key words

oral anticoagulants deep venous thrombosis pulmonary embolism practice guidelines 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151:933–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585–93.PubMedCrossRefGoogle Scholar
  3. 3.
    Hansson PO, Welin L, Tibblin G, Eriksson H. Deep vein thrombosis and pulmonary embolism in the general population. The ’Study of Men Born in 1913’. Arch Intern Med. 1997;157:1665–70.PubMedCrossRefGoogle Scholar
  4. 4.
    Ridker PM, Glynn RJ, Miletich JP, Goldhaber SZ, Stampfer MJ, Hennekens CH. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med. 1997;126:528–31.PubMedGoogle Scholar
  5. 5.
    Kniffin WD Jr, Baron JA, Barrett J, Birkmeyer JD, Anderson FA Jr. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med. 1994;154:861–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Ginsberg JS. Management of venous thromboembolism. N Engl J Med. 1996;335:1816–28.PubMedCrossRefGoogle Scholar
  7. 7.
    Goldhaber SZ. Pulmonary embolism. N Engl J Med. 1998;339:93–104.PubMedCrossRefGoogle Scholar
  8. 8.
    Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 1998;114:561S-78S.PubMedGoogle Scholar
  9. 9.
    Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest. 1989;95:37S-51S.PubMedGoogle Scholar
  10. 10.
    Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest. 1992;102:408S-25S.PubMedGoogle Scholar
  11. 11.
    Bright RA, Avorn J, Everitt DE. Medicaid data as a resource for epidemiologic studies: strengths and limitations. J Clin Epidemiol. 1989;42:937–45.PubMedCrossRefGoogle Scholar
  12. 12.
    Ray WA, Griffin MR. Use of Medicaid data for pharmacoepidemiology. Am J Epidemiol. 1989;129:837–49.PubMedGoogle Scholar
  13. 13.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373–83.PubMedCrossRefGoogle Scholar
  14. 14.
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Hansson P-O, Sörbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis. Arch Intern Med. 2000;160:769–74.PubMedCrossRefGoogle Scholar
  16. 16.
    Whittle J, Johnson P, Localio AR. Anticoagulation therapy in patients with venous thromboembolic disease. J Gen Int Med. 1998;13:373–8.CrossRefGoogle Scholar
  17. 17.
    Wenneker MB, Epstein AM. Racial inequalities in the use of procedures for patients with ischemic heart disease in Massachusetts. JAMA. 1989;261:253–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Goldberg KC, Hartz AJ, Jacobsen SJ, Krakauer H, Rimm AA. Racial and community factors influencing coronary artery bypass graft surgery rates for all 1986 Medicare patients. JAMA. 1992;267:1473–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Javitt JC, McBean AM, Nicholson GA, Babish JD, Warren JL, Krakauer H. Undertreatment of glaucoma among black Americans. N Engl J Med. 1991;325:1418–22.PubMedCrossRefGoogle Scholar
  20. 20.
    Glynn RJ, Gurwitz JH, Bohn RL, Monane M, Choodnovskiy I, Avorn J. Old age and race as determinants of initiation of glaucoma therapy. Am J Epidemiol. 1993;138:395–406.PubMedGoogle Scholar
  21. 21.
    Gornick ME, Eggers PW, Reilly TW, et al. Effects of race and income on mortality and use of services among Medicare beneficiaries. N Engl J Med. 1996;335:791–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Arnsten JH, Gelfand JM, Singer DE. Determinants of compliance with anticoagulation: a case-control study. Am J Med. 1997;103:11–17.PubMedCrossRefGoogle Scholar
  23. 23.
    White RH, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med. 1998;128:737–40.PubMedGoogle Scholar
  24. 24.
    Heit JA, Mohr DN, Silverstein MD, Petterson TM, O’Fallon WM, Melton LJ III. Predictors of recurrence after deep vein thrombosis and pulmonary embolism. Arch Intern Med. 2000;160:761–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Schulman S, Rhedini A-S, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med. 1995;332:1661–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Schulman S, Granqvist S, Holmström M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med. 1997;336:393–8.PubMedCrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 2000

Authors and Affiliations

  • David A. Ganz
    • 1
  • Robert J. Glynn
    • 1
  • Helen Mogun
    • 1
  • Eric L. Knight
    • 1
  • Rhonda L. Bohn
    • 1
  • Jerry Avorn
    • 1
  1. 1.the Program for the Analysis of Clinical Strategies, Division of Pharmacoepidemiology and PharmacoeconomicsBrigham and Women’s Hospital and Harvard Medical SchoolBoston

Personalised recommendations